Haleos
Haleos (HALEOSLABS) share price was ₹1,450.60 at the 28 Oct 2026 close; market capitalisation ₹439 Cr; P/E (TTM) 27.73; sector Healthcare. The share price rose 27.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 11.6% year on year to ₹72.94 Cr and net profit fell 58.1% year on year to ₹1.84 Cr (compared with Jun 2025). Promoters held 72.11% of Haleos in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 48/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,757.50 | 34.86 | 4,21,683 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,558.50 | 86.75 | 2,53,748 Cr | 15.14 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,557.00 | 71.54 | 1,73,334 Cr | 9.43 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,181.90 | 107.80 | 1,17,891 Cr | 22.24 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,175.50 | 26.16 | 1,17,257 Cr | 4.33 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,335.40 | 34.59 | 1,11,463 Cr | 2.87 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.60 | 32.72 | 1,10,321 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Haleos (this company) | ₹1,450.60 | 27.73 | 439 Cr | 2.05 | 0.10% | 7.75% | 10.61% | 327 Cr | 15 Cr |
| Median 8 companies | ₹1,604.05 | 34.73 | 1,17,574 Cr | 4.69 | 0.47% | 12.98% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
3- The company has delivered a poor sales growth of 4.68% over past five years.
- Company has a low return on equity of 8.23% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 12.5% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.65 | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.6 | 89.11 | 82.5 | 81.37 | 94.78 | 75.14 | 72.94 |
| Expenses | 72.11 | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 |
| Operating Profit | 2.54 | 7.93 | 9.3 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 |
| OPM % | 3.4% | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.5% |
| Other Income | 0.61 | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1 | 0.42 | 0.18 | 2.01 | 0.46 |
| Interest | 2.18 | 2.81 | 2.34 | 2.84 | 2.4 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.9 |
| Depreciation | 3.7 | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.8 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 |
| PBT | -2.73 | 1.66 | 3.81 | 7.1 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.9 | 3.44 |
| Tax % | 40.29% | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% |
| Net Profit | -3.83 | -0.44 | 4.12 | 6.47 | 7.1 | 3.3 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 |
| EPS (₹) | -5.95 | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.9 | 1.46 | 8.77 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 334 | 324 |
| Expenses | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 289 | 283 |
| Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 45 | 41 |
| OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 13% | 13% | 13% |
| Other Income | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 2 | 3 |
| Interest | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 7 | 6 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 | 16 |
| PBT | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 25 | 22 |
| Tax % | 30% | 31% | 31% | 23% | 31% | 36% | 28% | 29% | — |
| Net Profit | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 18 | 15 |
| EPS (₹) | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 57.26 | 52.31 |
| Div. Payout % | 3% | 0% | 3% | 2% | 4% | 5% | 2% | 3% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 |
| Borrowings | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 111 |
| Other Liabilities | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 130 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Fixed Assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 30 | 15 | 35 | -11 | 15 | 24 | 34 | 37 |
| Investing | -44 | -27 | -26 | -7 | -31 | -18 | -15 | -58 |
| Financing | 15 | 12 | -3 | 11 | 17 | -7 | -19 | 21 |
| Net Cash Flow | 1 | 0 | 6 | -8 | 0 | -1 | 0 | 1 |
| Free Cash Flow | 6 | -9 | 0 | -53 | -28 | 4 | 19 | -21 |
| CFO/OP | 105 | 69 | 133 | -10 | 62 | 88 | 94 | 98 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 | 73 | 67 |
| Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 | 163 | 210 |
| Days Payable | 140 | 101 | 163 | 146 | 127 | 143 | 129 | 162 |
| Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 | 107 | 116 |
| Working Capital Days | 14 | 18 | 2 | 17 | 24 | 11 | 7 | 5 |
| ROCE % | — | 12% | 13% | 12% | 8% | 7% | 12% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Haleos insights
69 extracted metrics + investor summaries across FY16–FY27.
Documents
Frequently Asked Questions about Haleos
What does Haleos Labs Limited do?
Where is Haleos Labs Limited (HALEOSLABS) listed?
Which sector does Haleos Labs Limited belong to?
What is the market capitalisation of Haleos Labs Limited?
What is the PE ratio of Haleos Labs Limited?
What is the 52-week high and low of Haleos Labs Limited?
Does Haleos Labs Limited pay dividends?
What is the Return on Equity (ROE) of Haleos Labs Limited?
Company Information
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HALEOSLABS.md for Haleos Labs Limited: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.